Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma.

Karl D. Lewis,Caroline Robert,Paolo A. Ascierto,Daniil Stroyakovskiy,Helen Gogas,Svetlana Protsenko,Rodrigo Perez Pereira,Thomas K. Eigentler,Piotr Rutkowski,Lev V. Demidov,Georgy M. Manikhas,Sara Tadesse-Bell,Kuan-Chieh Huang,V. McNally,Sohail Mulla,Grant A. McArthur,Ralf Gutzmer

Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma.

2020

Karl D. Lewis
Caroline Robert
Paolo A. Ascierto
Daniil Stroyakovskiy
Helen Gogas
Svetlana Protsenko
Rodrigo Perez Pereira
Thomas K. Eigentler
Piotr Rutkowski
Lev V. Demidov
Georgy M. Manikhas
Sara Tadesse-Bell
Kuan-Chieh Huang
V. McNally
Sohail Mulla
Grant A. McArthur
Ralf Gutzmer

10073Background: In IMspire150, A+C+V significantly improved investigator-assessed progression-free survival vs placebo (Pbo)+C+V in previously untreated pts with unresectable stage IIIc/IV BRAFV60...

Keywords:

Cobimetinib
Internal medicine
Oncology
Melanoma
Vemurafenib
Medicine
Atezolizumab
Pathology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations